Pliant Therapeutics, Inc.’s PLRX share price has dipped by 34.81%, which has investors questioning if this is right time to ...

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current ...

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO, ...

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion specializing in RNA interference (RNAi) technology, is on the cusp of a ...

Cells navigating in complex microenvironments frequently encounter narrow spaces that physically challenge migration.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate of 275,000 shares of common stock upon vesting to Delphine Imbert, ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

During cell adhesion, integrins are typically thought to require immobilized ligands for spreading. Here, the authors demonstrate that cells can spread and form mature integrin adhesions on fluid ...

During cell adhesion, integrins are typically thought to require immobilized ligands for spreading. Here, the authors demonstrate that cells can spread and form mature integrin adhesions on fluid ...

Explore the role of the extracellular matrix (ECM) in prostate cancer progression and discover natural therapies, including ...